Hay existencias
Tesamorelina: Un análogo de GHRH de 44 aminoácidos utilizado para investigar la regulación del eje de la hormona del crecimiento, la adiposidad visceral y las interacciones neuroendocrino-metabólicas.
$150.00
Hay existencias
La Tesamorelina es un péptido sintético compuesto por 44 aminoácidos y se clasifica como un análogo de la hormona liberadora de la hormona del crecimiento (GHRH). Se suministra como material de grado de investigación para laboratorios que estudian la regulación del eje hipotalámico-hipofisario, los puntos finales de la composición corporal y la señalización de tejidos periféricos vinculada a las vías de la GHRH.
La Tesamorelina ha sido diseñada para imitar y extender las características funcionales clave de la GHRH endógena. En entornos de investigación controlados, se utiliza como compuesto herramienta para estimular la liberación de la hormona del crecimiento hipofisaria y para estudiar los efectos posteriores sobre la señalización del factor de crecimiento similar a la insulina 1 y las vías metabólicas relacionadas. El péptido ha sido evaluado exhaustivamente en el contexto de la lipodistrofia asociada al VIH, donde la deposición disfuncional de grasa visceral es una característica central. El trabajo clínico y preclínico en esta población ha caracterizado cambios en el volumen del tejido adiposo visceral, marcadores hepáticos y metabólicos, y lecturas endocrinas tras la exposición protocolizada a la tesamorelina. Los estudios informan que la tesamorelina puede reducir la adiposidad visceral en aproximadamente un 20 por ciento en cohortes definidas de lipodistrofia asociada al VIH, con algunos análisis que sugieren un impacto varias veces mayor en la grasa visceral en comparación con otros enfoques terapéuticos disponibles evaluados en el mismo entorno. Programas de investigación adicionales están explorando la tesamorelina en modelos de salud del nervio periférico, deterioro cognitivo leve e interacciones neuroendocrinas metabólicas más amplias.
Este producto está destinado exclusivamente a experimentos in vitro, preparaciones ex vivo y otras aplicaciones de investigación de laboratorio controladas, incluidos estudios en animales o humanos realizados bajo la supervisión regulatoria y ética apropiada. Los usos típicos incluyen estudios mecanísticos de la señalización del receptor de GHRH, la modulación del eje de la hormona del crecimiento y la regulación de la composición corporal en investigación metabólica y neuroendocrina. No está destinado para uso humano o veterinario sin supervisión. Fuera de los protocolos clínicos aprobados, no está destinado para el diagnóstico, tratamiento, cura, prevención o mitigación de ninguna enfermedad o condición médica. No es un alimento, suplemento dietético, cosmético o producto de venta libre.
Análogo sintético de GHRH de 44 aminoácidos adecuado para la investigación del eje de la hormona del crecimiento. Ampliamente caracterizado en ensayos de lipodistrofia asociada al VIH con efectos documentados sobre el tejido adiposo visceral en esa población específica. Aplicable en estudios de señalización neuroendocrina, puntos finales relacionados con el nervio periférico, modelos de envejecimiento cognitivo y regulación de la composición corporal.
Tesamorelin is a synthetic forty four amino acid analogue of growth hormone releasing hormone. It is used in controlled research to study growth hormone axis regulation visceral adiposity and neuroendocrine signaling in specific clinical and preclinical settings. The summary below reframes the data strictly as research context for a GHRH analogue. Nothing here is a usage claim and none of it should be read as guidance for off protocol administration.
Tesamorelin shares the core mechanism of endogenous GHRH and other GHRH analogues such as sermorelin GRF 1 29 and CJC 1295. The molecule incorporates a trans 3 hexanoic acid modification that increases stability in human plasma and prolongs half life compared with native GHRH. Despite its extended half life tesamorelin preserves the pulsatile pattern of growth hormone release rather than imposing constant non physiological elevation. This preservation of hypothalamic pituitary dynamics is a key focus of comparative pharmacology studies that contrast tesamorelin with agents that flatten normal growth hormone rhythms. Researchers use these models to examine how different GHRH analogue designs influence downstream IGF 1 signaling metabolic endpoints and side effect profiles when growth hormone dynamics are preserved versus overridden.
The most extensively studied indication for tesamorelin is HIV associated lipodystrophy. This condition involves abnormal visceral and ectopic fat accumulation that arises from both chronic HIV infection and adverse effects of antiretroviral therapy particularly protease inhibitors. Before tesamorelin options for this population included diet and exercise modestly active pharmacologic agents and surgical approaches with variable outcomes. Clinical trials demonstrated that tesamorelin can reduce visceral adipose tissue by roughly twenty percent in people with HIV associated lipodystrophy who meet protocol criteria. Comparative analyses suggest that in this defined setting tesamorelin produces approximately fourfold larger reductions in visceral adiposity than the combined effect of other available medical therapies.
These data supported regulatory approval of tesamorelin for HIV associated lipodystrophy in 2010 and continue to guide mechanistic work on growth hormone axis targeting in ectopic fat disorders.
People living with HIV have elevated cardiovascular risk that reflects abnormal fat distribution chronic inflammation and direct drug effects. Research programs therefore examine tesamorelin not only for changes in visceral adiposity but also for shifts in cardiometabolic biomarkers. Studies in HIV positive cohorts show that tesamorelin associated reductions in visceral adipose tissue correlate with improvements in triglycerides total cholesterol and non HDL cholesterol. For example a fifteen percent decrease in visceral adipose tissue has been associated with about a fifty milligram per deciliter reduction in triglyceride levels in responders. Since visceral adipose tissue liver fat and epicardial fat are each independently linked to cardiovascular disease risk these findings support the use of tesamorelin as a probe to study how targeted changes in ectopic fat and inflammation might alter long term cardiometabolic trajectories in this high risk group.
Highly active antiretroviral therapy is associated with several endocrine and metabolic disturbances including a higher prevalence of growth hormone deficiency.
Evidence suggests that both HIV infection and its treatment can alter pituitary function leading to growth hormone deficits in a significant fraction of patients on HAART.
This observation provides a mechanistic framework for why lipodystrophy is common and why restoring physiologic growth hormone axis activity with a GHRH analogue such as tesamorelin may have targeted effects on visceral fat and metabolic markers. Research comparisons between tesamorelin and direct growth hormone replacement emphasize that GHRH analogues maintain regulatory feedback and pulsatility while exogenous growth hormone bypasses hypothalamic control. These differences are central to current investigations of safety and efficacy in HIV related metabolic disorders.
Peripheral nerve injury from trauma diabetes or surgery is a major cause of sensory and motor impairment. Preclinical work indicates that growth hormone axis modulation can influence nerve regeneration speed and completeness. Tesamorelin has emerged as a leading candidate in this line of investigation because it already has an established safety and pharmacokinetic profile in other indications. Animal and early translational studies examine functional recovery conduction velocities and histologic markers of nerve repair under protocols that incorporate tesamorelin or related GHRH analogues. These programs are designed to determine whether upstream growth hormone axis activation can be harnessed to support peripheral nerve healing in a controlled way.
Cognitive aging and early dementia represent another active area of GHRH analogue research. A large randomized double blind placebo controlled study run at the University of Washington School of Medicine evaluated GHRH analogues including tesamorelin in adults with mild cognitive impairment and in older adults without diagnosed dementia.
Over a twenty week period investigators assessed executive function verbal memory and neurochemical markers using spectroscopy and cognitive testing.
Results indicated that GHRH analogue exposure could improve executive function and verbal memory measures in mild cognitive impairment and could modulate brain metabolites such as gamma aminobutyric acid and myo inositol in directions considered favorable. These data suggest that growth hormone axis modulation may influence brain aging pathways and open additional lines of inquiry into dementia mechanisms without establishing tesamorelin as a dementia therapy at this stage.
Across the literature tesamorelin is used in growth hormone releasing hormone receptor and pituitary axis studies HIV associated lipodystrophy and ectopic fat distribution trials cardiometabolic risk and lipid profile investigations in HIV positive populations endocrine research on HAART related growth hormone deficiency peripheral nerve injury and regeneration models cognitive aging and mild cognitive impairment studies focused on GHRH analogues. In every application tesamorelin functions as a controlled GHRH analogue for mechanistic and clinical research rather than as a general purpose weight loss or performance agent.
All findings summarised here arise from regulated clinical trials animal studies and in vitro work conducted under defined protocols.
They are presented solely to inform qualified researchers about how tesamorelin is being used to study growth hormone axis biology and metabolic disease.
These observations do not demonstrate or imply that tesamorelin is safe or appropriate for unsupervised use in the general population.
They are not dosing instructions medical advice or guidance for weight loss anti aging cognitive enhancement or any off label purpose.
Tesamorelin supplied in a research catalog is intended strictly for laboratory and protocol based research applications.
It is not for human or veterinary use outside approved clinical studies and must not be used for diagnosis treatment cure prevention or mitigation of any disease or condition.»
$95.00
BPC 157: Un pentadecapéptido sintético utilizado en modelos de laboratorio para investigar la angiogénesis, la migración de fibroblastos y la integridad de la barrera mucosa.
$50.00
BPC 157: Un pentadecapéptido sintético utilizado en modelos de laboratorio para investigar la angiogénesis, la migración de fibroblastos y la integridad de la barrera mucosa.
$95.00
KPV 10 mg: Un fragmento de alfa-MSH acetilado utilizado como herramienta de investigación para indagar en las vías de señalización inflamatoria y los mecanismos de transporte epitelial.
$85.00
PT-141 10 mg: Agonista sintético del receptor de melanocortina (MC3R/MC4R) utilizado para estudiar la farmacología de los GPCR y las redes de señalización hipotalámica en modelos de laboratorio.
